NFKB1 and breast carcinoma: EZH2 is indeed known to repress transcription by participating in histone mark H3K27me3 deposition as well as DNA methylation31, although it also functions as a double-faceted molecule in breast cancers, either as a transcriptional activator or repressor of NF-kB targets, depending on the cellular context32.